A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT05630183
- Locations
- πΊπΈ
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈUSC Norris Oncology, Newport Beach, California, United States
πΊπΈIllinois Cancer Specialists, Arlington Heights, Illinois, United States
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT05608044
- Locations
- πΊπΈ
HonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈMemorial Sloan Kettering, New York, New York, United States
π·πΊBranch office of " Hadassah Medical Ltd", Moscow, Russian Federation
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
- Conditions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT05572970
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05529316
- Locations
- π§πͺ
Universitair Ziekenhuis Brussel, Jette, Belgium
πͺπΈHospital Clinic Barcelona, Barcelona, Spain
πͺπΈConsorcio Hospital General Universitario de Valencia, Valencia, Spain
Study of AGEN1571 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05377528
- Locations
- πΊπΈ
Florida Cancer Specialists, Sarasota, Florida, United States
πΊπΈIcahn School of Medicine at Mount Sinai, New York, New York, United States
πΊπΈSarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT05033132
- Locations
- π¨π³
Betta Clinical Study Site 27, Wuhu, Anhui, China
π¨π³Betta Clinical Study Site 10, Zhanjiang, Guangdong, China
π¨π³Betta Clinical Study Site 43, Wuhan, Hubei, China
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT04943627
- Locations
- π¦π²
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
π¦π²National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
πΊπΈOptimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT04607200
A Study in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04156100
- Locations
- πΊπΈ
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈHonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈUniversity of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT04121676
- Locations
- πΊπΈ
Mary Crowley Cancer Research Center, Dallas, Texas, United States
πΊπΈRoswell Park Comprehensive Cancer Care, Buffalo, New York, United States
πΊπΈColumbia University, New York, New York, United States